

WELCOME

Dear Colleagues,

On behalf of Retina Consultants, Ltd., University of Chicago and University of Illinois Eye and Ear Infirmary it is our honor to welcome you ROP HOT TOPICS Chicago!

We are pleased to have you participate in this important program. We are all on the same journey to improve the lives of our patients; however limited data forces us to navigate through difficult clinical challenges at many levels.

The objective of this meeting is to allow an exploration and encourage discussion of key aspects of ROP that inform clinical management, now and in the future.

Many thanks to all the members of the Program Committee, Faculty, and volunteers who have worked hard to create a dynamic program.

A special thank you to our Section Organizers Peter Campbell, Mary Elizabeth Hartnett, Michael Msall and Haresh Kirpalani.

Also, gratitude to our volunteer organizers Mark Solinski, April Ingram, Kate Lewis and Aneta Firoz.

We look forward to joining you as you continue your vital work to improve the diagnosis, management and treatment of ROP.

Warmest Regards,

ROP HOT TOPICS Organizing Committee



Michael Shapiro, MD



Michael Blair, MD



Anna Ells, MD, FRCS(C)



Sarah Rodriguez, MD, MPH



RV Paul Chan, MD, FACS

Thank you to our sponsors for their support and contributions to this program

ROP HOT TOPICS Organizing Committee

Alcon A Novartis
Division

natus *Leica*
MICROSYSTEMS

BAUSCH + LOMB
See better. Live better.

ROP
Hot Topics 2018

Meeting Wifi Network: UClub

Password: 1234567890

ROP Hot Topics Agenda

Tuesday, October 30, 2018			
500 PM	Michigan/Monroe Rooms	Reception	
630 pm	Cathedral Room	Dinner	
700 pm	Cathedral Room	International ROP	
	700-710	Guest of Honor	
	710-720	Marilyn Miller	International Ophthalmology
	720-730	Paul Chan	International Ophthalmology and Education
	730-740	Subhadra Jalali	Visual, refractive and anatomical outcomes in clinical practice of 15 years of ROP in the Indian Twin cities ROP study database (ITCROPS).
	740-750	Discussion	
750pm	Cathedral Room	Macular Structure after Anti VEGF Moderators: Pete Campbell and Wei-Chi Wu	
	750-800	Hirouki Kondo	OCTA in children who had a history of ROP
	800-810	Deborah Costakos	Foveal development in infants treated with bevacizumab or laser photocoagulation for retinopathy of prematurity.
	810-820	Wei-Chi Wu	Macular Structures, Optical Components, and Visual Acuity in Preschool Children after Intravitreal Bevacizumab or Laser Treatment
	820-830	Sarah Hilkert Rodriguez	Visual and Refraction Outcomes of Laser Ablation and Bevacizumab in Management of ROP
	830-845	Discussion	
Wednesday, October 31, 2018			
700am Breakfast in Cathedral Room			
730am	Cathedral Room	How to Understand and Use Animal Models Moderator: Mary Elizabeth Hartnett	
	730-745	Mary Elizabeth Hartnett	Mueller cells and VEGF inhibition
	745-800	Lois Smith	Oxygen Induced Retinopathy Mouse Model
	800-815	Mahnaz Shahidi	Imaging of Retinal Oxygen Extraction, Vascularization, and Thickness in Oxygen-induced Retinopathy
	815-830	Amani Fawzi	Using Metabolic Retinal Vascular Imaging to Understand ROP Pathology-Visible-light OCT
	830-845	Discussion	
845am	Cathedral Room	How to Use Anti-VEGF Effectively Moderator: Audina Berrocal	
	845-855	Armie Harper	SAFER technique for the treatment of Type 1 ROP
	855-905	Catherin I Negron	How To Successfully Manage a ROP Service in an Anti-VEGF Era
	905-915	Discussion	

915am	Cathedral Room	Difficult ROP Moderators: Michael Shapiro and Subhadra Jalali	
	915-925	Audina Berrocal	Management of Difficult Cases of ROP
	925-935	Rajvardhan Azad	Posterior Laser Barrage in Advancing Retinopathy of Prematurity: A prospective randomized study.
	935-945	Discussion	
945-1015	Michigan/Monroe Rooms	Posters/Vendors	
	Northwestern Room	Breakout Stage 5 ROP Surgical Pearls/Discussion: Subhadra Jalali	
1015am	Cathedral Room	Systemic Factors in ROP	
	1015-1025	Shira Robbins	What we know about ROP and Omega-3 fatty acids
	1025-1045	Michael Gaynon	Prethreshold retinopathy of prematurity: VEGF inhibition without VEGF inhibitors
	1045-1055	Discussion	
1055am	Cathedral Room	Recurrence after Anti-VEGF: Moderator: Wei-Chi Wu	
	1055-1105	Michael Blair	Reactivation after Bevacizumab
	1105-1115	Shunji Kusaka	Systemic VEGF and Recurrence after Intravitreal Ranibizumab for ROP
	1115-1125	Discussion	
1125-1145	Cathedral Room	RAINBOW Study	
		Domenico Lepore	Ranibizumab for the treatment of retinopathy of prematurity (ROP): 24-week results from the randomized, multi-center, open-label RAINBOW study
1145-1205	Cathedral Room	Evaluation of Evidence and Data	
		Gil Binenbaum	Big data, Biased data, and Good data: Evidence in ROP
1205-105pm	LUNCH	Michigan/Monroe Rooms	
105pm	Cathedral Room	Free Paper	
	105-115	Robert Arnold	Factors Associated with Retinopathy of Prematurity Ophthalmology Exam Workload
120pm	Cathedral Room	Neurodevelopment Session 1: Ophthalmology Perspectives Moderators: Armie Harper and Anna Ells	
	120-130	Anna Ells	Recurrence and Neurodevelopmental Outcomes Following intravitreal Ranibizumab Injection for Retinopathy of Prematurity
	130-140	Wei-Chi Wu	Neurodevelopmental Outcomes Following Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: a prospective, case-control study
	140-150	Maram Isaac	Neurodevelopmental Outcomes in Infants with Retinopathy of Prematurity treated with Bevacizumab versus Laser
	150-200	Kamiar Mireskandari	Effect of Anti-VEGF Treatment for Retinopathy of Prematurity on Major Body Organs: An In Vivo Study
	200-215	Discussion	

215-245pm	Michigan/Monroe Rooms	Poster/Sponsors	
245pm	Cathedral Room	Neurodevelopmental Outcomes in High Risk Preterm Infants: Clinical Trials, Measures, and Safety. Moderators: Michael Msall and Michael Blair	
	245-315	Heresh Kirpalani	Lessons from Clinical Trials in promoting safety and neuroprotection
	315-345	Bree Andrews	Neonatal morbidities (BPD, NEC, Sepsis, and Sonographic Brain Injury), Zip Code, and biomarkers: Information at discharge that predict Bayley Outcomes
	345-400	Bree Andrews & Michael Msall	What does the Bayley 3 measure and what items are dependent on motor or visual skills? Limitations of the Bayley 3 for children with evolving visual and neuromotor disability
400-415	BREAK		
	415-430	Ellen Choi	Anesthesia and Neurotoxicity: Caution and Care
	430-500	Michael Msall	Assessing neurodevelopmental trajectories in high risk preterm infants through apps and engagement - Lessons from cryo rop and neuroprotection
	500-515	Sarah Hilkert Rodriguez	Neurodevelopment: Lessons and Opportunities.
	515-545	Discussion	
545pm	Northwestern Room	Breakout Session: Can we organize a large collaborative network for neurodevelopment?	
Thursday November 1, 2018			
700am Breakfast in Cathedral Room			
730am	Cathedral Room	How to Understand Deep Learning Moderator: Peter Campbell	
	730-745	James Brown	Basics of Deep Learning
	745-800	Alay Banker	Deep learning-based system for automated diagnosis of plus disease
	800-815	Peter Campbell	Desk to bedside: translating advances in artificial intelligence into improved care for retinopathy of prematurity
	815-830	Discussion	
830am	Cathedral Room	How to Use and Understand Modern Imaging Modalities. Moderators Michael Blair and Peter Campbell	
	830-840	Michelle Cabrera	Punctate Hyperreflective Vitreous Opacities Visualized by Handheld Spectral Domain Optical Coherence Tomography in Premature Infants Screened for Retinopathy of Prematurity
	840-850	Peter Campbell	OCT/OCTA in ROP
	850-900	Discussion	
	900-910	Maria Ana Martinez Castellanos	Posterior segment photography in premature babies using the ultra-widefield camera OPTOS
	910-920	Domenico Lepore	FA after anti-VEGF
	920-930	Discussion	

930am	Cathedral Room	Updating Language for ROP: Standardization for New Observations Moderators: Michael Shapiro and Alistair Fielder	
	930-940	Alistair Fielder	Describing ROP: Current Limitations and New Challenges
	940-950	Birgit Lorenz	Proposal of a refined zone classification in acute ROP
	950-1000	Anna Ells	Nomenclature for Recurrence
	1000-1010	Subhadra Jalali	Variable Retinal vascularity at birth provides insights to ROP vulnerability, classification and effects of Anti-VEGF therapies
	1010-1020	Discussion	
1020-1050am	Michigan/Monroe	Posters/Vendors	
1020-1050am	Northwestern Room	Breakout Session: Nomenclature: Can We Update ICROP	
1050am	Cathedral Room	How to Understand Telemedicine Moderators: Anna Ells and Lloyd Hildebrand	
	1050-1110	Lloyd Hildebrand	Perspectives and Overview in Telemedicine for ROP – A Literature Review
	1110-1120	Peter Campbell	Tele-Education for ROP and Common Errors in ROP Diagnosis
	1120-1130	Graham Quinn	The e-ROP Study and Future Directions
	1130-1140	Narendran Venkatapathy	The Arevind Hospital Telemedicine ROP Program
	1140-1150	Alay Banker	Development of Smartphone-Based ROP Examination Device
	1150-1200	Discussion	
1200-100pm	LUNCH	Michigan/Monroe Rooms	
100pm	Cathedral Room	Variable Dosing Strategies Moderator: Anna Ells	
	100-110	David Wallace	Bevacizumab De-escalation Dosing
	110-120	Amit Bhatt	Experience with Lower Dose of Avastin
	120-130	Discussion	
130pm	Cathedral Room	APROP Moderator: Michael Shapiro	
	130-140	Birgit Lorenz	Lessons learned from treating APROP: A consecutive case series imaged with fluorescein angiography
	140-150	Alay Banker	Primary Monotherapy Anti-VEGF treatment of APROP: One-year follow-up results of more than 100 eyes
	150-200	Discussion	
200pm	Cathedral Room	Perspectives on AntiVEGF treatment for ROP	
	200-210	Graham Quinn	AntiVEGF Treatment for Type 1 ROP: An Unsettled Issue
	210-220	Michael Shapiro	Anti-VEGF for ROP: A Decade of Confusion
	220-230	Discussion	

230-300pm	Michigan/Monroe	Posters/Vendors	
300pm	Cathedral Room	Advanced/Late ROP Moderator: Michael Shapiro	
	300-310	Maria Ana Martinez Castellanos	3 Years follow up after stage 5 ROP surgery with radiofrequency membranectomy
	310-320	Hideyuki Hayashi	Late Retinal Detachment on Retinopathy of Prematurity (ROP) Following Ablative Retinal Coagulation
	320-330	Andres Kychenthal	Management of Progressive ROP
	330-340	Iris Kassem	Findings in Persistent Retinopathy of Prematurity
	350-400	Discussion	
400pm	Cathedral Room		
	400-210	Andres Kychenthal	ROP in Chile 1995-2018
	410-220	Linda Lawrence	Cortical Visual Impairment in Children with ROP
	420-430	Atchara Amphornphruet	Late ROP progression or delay fibrovascular contraction after anti-vegf injection
POSTERS	Deborah Costakos	Histopathological Analysis of ROP after Intravitreal Bevacizumab	
	Molly Scripture	Glaucoma and ROP Treated with Bevacizumab	
	Kassem/Costakos	Conjunctival Ocular Flora Before and After Povidine Iodine in Neonates	
	Kassem/Costakos	Clinical Course and Treatment Rates of ROP in Extremely Premature Infants Born at Under 26 weeks Gestational Age	
	Jose Garcia	Posterior Foveal Development	
	Elise Timtim	Treatment of Retinopathy of Prematurity with Intravitreal Bevacizumab in Infants Weighing 500 Grams or Less at Birth	
	Christos Theophanous	Bilateral Vitreous Hemorrhage Following Bilateral Intravitreal Injections of Bevacizumab in an Infant with Retinopathy of Prematurity	
	Michael H Zhang	Ocular and neurodevelopmental outcomes among infants treated for retinopathy of prematurity using a commercial claims database.	
	Julia Schulman	The Rat Fluctuating Oxygen-induced Retinopathy model adapted to clarify disparity in observational studies of premature infants	
	Nandita Anand	Refractive Outcomes after Anti-VEGF and Laser	
	Supalert Prakhunhungsit	The Successful Non-Surgical Treatment for Surgical Retinopathy of Prematurity Cases.	
	Subhadra Jalali	Prospective clinical study of two different regimens of combined laser photocoagulation and intravitreal bevacizumab treatment for retinopathy of prematurity.	
	Michael Gaynon	Prethreshold retinopathy of prematurity: VEGF inhibition without VEGF inhibitors	